Fluorescence Diagnosis and Photodynamic Therapy of Skin Diseases

Atlas and Handbook

AvClemens Fritsch,Thomas Ruzicka

Inbunden, Engelska, 2003

1 637 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Fler format och utgåvor

Häftad

1 637 kr

Beskrivning

The main part of the book focuses on the clinical aspects giving detailed descriptions on skin tumor detection as well as photodynamic treatment of selected diseases (solar keratoses, basal cell carcinomas, squamous cell carcinomas, Bowen's disease, psoriasis lesions, etc.).

Produktinformation

Utgivningsdatum:2003-06-17
Mått:215 x 285 x 14 mm
Vikt:655 g
Format:Inbunden
Språk:Engelska
Antal sidor:128
Förlag:Springer Verlag GmbH
ISBN:9783211838273

Utforska kategorier

Diagnostiska metoder inom Medicin
Dermatologi inom Medicin

Innehållsförteckning

A Introduction and Historical Landmarks.- A.1 Definition of the Photodynamic Action.- A.2 Optimum Photosensitizing Agent for Photodynamic Action.- A.3 Definition of Fluorescence Detection with ALA-Induced Porphyrins (FDAP).- A.4 Mechanisms of Action in PDT.- B ?-Aminolevulinic Acid (ALA).- B.1 Chemistry of ALA and ALA Methylester (ALA).- B.2 Metabolism of ALA.- B.3 Pharmacodynamics of ALA.- C Light Used in FDAP and PDT.- D Unresolved Issues in FDAP and PDT.- E Fluorescence Detection of ALA-induced Porphyrins (FDAP).- E.1 FDAP: Evaluation of the ALA-Induced Fluorescence in Skin Diseases.- F Ex vivo — Investigations on ALA-induced Porphyrins.- F.1 Porphyrin Accumulation in Cells (in vitro).- F.2 Porphyrin Accumulation in Skin Tumors, Colon and Bronchial Carcinomas after Administration of ALA (ex vivo).- G In vivo — Investigations on ALA-Induced Porphyrin/FDAP.- G.1 FDAP: Kinetics of ALA-Induced Porphyrins in Human Cutaneous Tumors, Psoriasis Lesions and Normal Skin.- G.2 FDAP: Kinetics of Porphyrin Accumulation in Solar Keratoses: ALA versus ALA Methylester.- G.3 FDAP: Use of the in vivo — Fluorescence for Surgical Planning.- G.4 FDAP: Evaluation of the Optimum Photosensitizing Substance or its Prodrug.- G.5 FDAP: Evaluation of the Optimum Exciting Light Source.- G.6 FDAP: Correlation of in vivo — Tumor Fluorescence and Histopathology.- G.7 FDAP: Course of FDAP in Relation to the Number of PDT-Sessions.- H The Clinical Use of FDAP.- H.1 FDAP in Clinically Well-defined Tumors.- H.2 FDAP in Clinically Ill-defined Lesions.- H.3 FDAP in Pretreated or Damaged Skin.- H.4 Limitations of FDAP.- H.5 Usefulness of FDAP in Guiding Tumor Therapies.- I Photodynamic Therapy in Cutaneous Diseases.- I.1 PDT: Evaluation of the Efficacy in Solar Keratoses.- I.2 PDT: Evaluation ofthe Efficacy in Bowen’s Disease.- I.3 PDT: Evaluation of the Efficacy in Basal Cell Carcinoma.- I.4 PDT: Evaluation of the Efficacy in Squamous Cell Carcinoma.- I.5 PDT: Evaluation of the Efficacy in Psoriatic Lesions.- I.6 PDT: Evaluation of the Efficacy in Selected Cutaneous Diseases.- I.7 PDT: Evaluation of the Optimum Photosensitizing Substance or its Prodrug.- I.8 PDT: Evaluation of the Optimum Exciting Light Source.- J General Discussion.- J.1 FDAP: Indications and Limits.- J.2 PDT: Indications and Limits.- J.3 Safety and Tolerability of ALA-PDT.- J.4 Regulatory Affairs Concerning Aminolevulinic Acid.- J.5 Regulatory Affairs Concerning Aminolevulinic Acid Methylester.- K Conclusion.- L Summary.- Acknowledgements.